Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group.
Ringdén O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindeløv L, Parkkali T, Lenhoff S, Sallerfors B, Ljungman P, et al. Ringdén O, et al. Among authors: lenhoff s. Blood. 1994 May 1;83(9):2723-30. Blood. 1994. PMID: 8167351 Free article. Clinical Trial.
No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group.
Ruutu T, Ljungman P, Brinch L, Lenhoff S, Lönnqvist B, Ringdén O, Ruutu P, Volin L, Albrechtsen D, Sallerfors B, Ebeling F, Myllylä G. Ruutu T, et al. Among authors: lenhoff s. Bone Marrow Transplant. 1997 Feb;19(3):233-6. doi: 10.1038/sj.bmt.1700649. Bone Marrow Transplant. 1997. PMID: 9028551 Clinical Trial.
Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group.
Ringdén O, Remberger M, Ruutu T, Nikoskelainen J, Volin L, Vindeløv L, Parkkali T, Lenhoff S, Sallerfors B, Mellander L, Ljungman P, Jacobsen N. Ringdén O, et al. Among authors: lenhoff s. Blood. 1999 Apr 1;93(7):2196-201. Blood. 1999. PMID: 10090927 Free article. Clinical Trial.
Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group.
Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL, Wislöff F, Brinch L, Carlson K, Carlsson M, Dahl IM, Gimsing P, Hippe E, Johnsen HE, Lamvik J, Löfvenberg E, Nesthus I, Rödjer S. Lenhoff S, et al. Blood. 2000 Jan 1;95(1):7-11. Blood. 2000. PMID: 10607678 Free article. Clinical Trial.
117 results